ANIX

Anixa is a clinical-stage biotech with no operating business to value: management states plainly it 'did not have any revenue in fiscal years 2025 and 2024,' and the only revenue in the figures is legacy patent-licensing income management says it does 'not expect... to be a significant part of the Company's ongoing operations.' The headline P/S of 453x is therefore noise — there is nothing to anchor a price to except trial outcomes that the data does not contain. The entire equity value ($95.1M market cap) is a bet on the breast-cancer vaccine and CAR-T programs eventually being licensed to big pharma, which the filing concedes 'may take several years, if it is to occur at all, and may depend on positive results from human clinical trials.' With no efficacy data provided, the forward outcome is genuinely unknowable — the rubric's definition of avoid.

The balance sheet is the one bright spot but it is shrinking, not strengthening. Equity is $15.2M against just $2.13M of liabilities (0.14x), essentially debt-free, and working capital was ~$13.9M. But total assets fell 25.5% YoY and the company is structurally loss-making: a $10.9M net loss, $11.7M operating loss, and -$7.17M operating cash flow against only $1.24M of cash and equivalents (the larger $15.2M figure includes short-term investments). On that ~$7M annual burn the company has roughly two years of runway, consistent with management's 'at least the next twelve months' guidance — after which it must raise. The $252M accumulated deficit is the track record: two decades of cash consumption with no commercialized product.